Search

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

Enhancing glaucoma awareness and management in Nigeria – from grass roots to national policy development

This is the second in a series (see Part 1 here) of three articles about strengthening eye health services in Nigeria through collaboration with the LINKS and Networks run at the International Centre for Eye Health, LSHTM. This article highlights...

DR-NET National DR Workshop in Tanzania: Policy, training and technology

Diabetic retinopathy (DR) is a leading cause of moderate to severe visual impairment (VI) and blindness worldwide, posing a significant public health challenge. As the prevalence of diabetes continues to rise globally, particularly in low- and middle-income countries (LMICs), the...

PACK-crosslinking for infectious keratitis

Corneal cross-linking with riboflavin and UV-A light (CXL) is a technology that has been initially developed to treat corneal ectatic disorders [1]. Its effect in stabilising diseases such as keratoconus was reported in numerous trials with excellent long-term outcomes and...

Retinal prosthetics: science fiction or a vision for the future?

“Is it a fact – or have I dreamt it – that, by means of electricity, the world of matter has become a great nerve, vibrating thousands of miles in a breathless point of time?” – Nathaniel Hawthorne, The House...

FAQs about cerebral visual impairment (CVI): identifying and helping those affected

Cerebral visual impairment is common in both adults and children, yet the diagnosis can easily be missed unless one is tuned into the presenting features. This article provides a succinct introduction to this important topic. What is vision? Vision is...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

The ROP Network: a south-south collaboration to improve care for premature babies

Retinopathy of prematurity (ROP) is a disorder of the immature preterm retina and a leading cause of preventable, irreversible blindness in children. There are 15 million preterm births annually, and over 32,000 neonates became blind from ROP in 2010 [1]....

Glaucoma: 30 years on

Back in 1993, the late and great Barry Cullen FRCS (Cavan born, Dublin trained), the first editor of Eye News, asked me to write an article about the current treatment of chronic open angle glaucoma (COAG). At the time I...

Part 3: The Arclight Project: Implementation workshops

In this three-part series (Click here for Part 1 and Part 2) Andrew Blaikie and his team explore the role and application of the Arclight Device in Imaging of the Eye. The Arclight Project aims to support and enhance the...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...